sunovion.comInnovative Treatments, Science and Technology | Sumitomo Pharma America, Inc.

Newsroom NewsroomJoin Us Contact UsSMPA LegacyLeadership Affiliates Science Focus Areas Pipeline Clinical Trials Scientific PublicationsProducts Myfembree Gemtesa Latuda Aptiom Orgovyx RethymicProducts Technology Our Impact StoriesDedicated to improving the health and well-being of people around the world. We drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapy. Learn More Discovering Sumitomo Pharma America (SMPA) Innovation growth engine Drug discovery, development, and commercialization must become faster and more efficient to address humanity’s health needs. SMPA embodies the bold promise of combining technology and life-sciences expertise to measurably improve patient outcomes. Learn More Diverse pipeline Our preclinical and clinical programs span numerous modalities and indications where patient needs remain high or unmet. Our Pipeline Fueling breakthroughs Delivering patient-first solutions sooner through a technology-driven approach. Our Technology NEWS & SCIENTIFIC PUBLICATIONSNEWS The latest from SMPANews | July 2023 Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities News | April 2023 Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder News | April 2023 Sumitomo Pharma Subsidiaries, Including Sumitomo Pharma America Holdings, to Combine and Form Sumitomo Pharma AmericaNewsroom NewsroomJournal of Gerontological Nursing | Jul. 1, 2022 Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities: A Perspective From Directors of Nursing Pulmonary Circulation | Apr. 29, 2022 A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2) International Journal of Clinical Practice | Apr. 13, 2022 Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial Scientific PublicationsStories Through storytelling, we shine a light on stigma, science, and community through videos, articles, and more. View more stories Menstrual Mysteries—Mothers and Daughters Talk About Periods Menstrual Mysteries—Mothers and Daughters Talk About Periods Watch video series Men with Prostate Cancer Find Support A video series on how men with prostate cancer find strength in community. Watch video series Why Overactive Bladder Deserves Our Attention Overactive bladder is more than just a physical condition; it’s a life-altering challenge affecting millions. Learn more 3 Ways to Improve Endometriosis Diagnosis Getting a diagnosis for endometriosis can take years. Why does this happen? View infographic Science Products Technology Our Impact StoriesNewsroom Join Us Contact Us LinkedIn LinkedIn YouTubePrivacy Notice Terms Of Use Medical Disclaimer Social Media Community Guidelines Accessibility Statement Corporate Transparency Documents is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. © Sumitomo Pharma America, Inc. All rights reserved. × × ×You are now leaving us.sumitomo-pharma.com and moving to an external web site that is independently maintained by a third party. Sumitomo Pharma America, Inc. (SMPA) is not responsible for the information contained in any of the linked sites. Please review the external web site’s Privacy Policy, as it is different from SMPA’s. Click CONTINUE to proceed to this link, or CANCEL to return to us.sumitomo-pharma.com. Cancel...